<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Dipyrone is an <z:chebi fb="0" ids="35493">antipyretic</z:chebi> and <z:chebi fb="29" ids="35480">analgesic</z:chebi> medicine very used by the Brazilian population </plain></SENT>
<SENT sid="1" pm="."><plain>The administration is considered safe even in pregnant women, nurseling and children, but is forbidden in some countries, as supposedly causes <z:mp ids='MP_0000334'>agranulocytosis</z:mp> and <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In 2001, National Health Surveillance Agency (Anvisa) approved the commercialization of this medicine in Brazil </plain></SENT>
<SENT sid="3" pm="."><plain>However, it does not matter the safeness in the use of a medicine advances, if it does not have quality </plain></SENT>
<SENT sid="4" pm="."><plain>Based on this quality, this work was elaborated, that analyzes seven samples of commercialized different marks of dipyrone oral solution in pharmaceutical establishment in the Cascavel city, Paran√°, Brazil </plain></SENT>
<SENT sid="5" pm="."><plain>The results demonstrate that the quality control of similar drugs must be improved as were the ones that presented quality deviations </plain></SENT>
</text></document>